These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23594312)

  • 21. HPTN 052 and the future of HIV treatment and prevention.
    Cates W
    Lancet; 2011 Jul; 378(9787):224-5. PubMed ID: 21763928
    [No Abstract]   [Full Text] [Related]  

  • 22. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.
    Baeten J; Celum C
    Annu Rev Med; 2013; 64():219-32. PubMed ID: 23020883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA.
    Kurtz SP; Buttram ME; Surratt HL
    AIDS Care; 2014 Apr; 26(4):411-5. PubMed ID: 24033118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cultural conundrums: the ethics of epidemiology and the problems of population in implementing pre-exposure prophylaxis.
    Fiereck K
    Dev World Bioeth; 2015 Apr; 15(1):27-39. PubMed ID: 24373050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving adherence and clinical outcomes through an HIV pharmacist's interventions.
    Ma A; Chen DM; Chau FM; Saberi P
    AIDS Care; 2010 Oct; 22(10):1189-94. PubMed ID: 20640958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current status of the use of oral medication to prevent HIV transmission.
    Mayer KH; Ramjee G
    Curr Opin HIV AIDS; 2015 Jul; 10(4):226-32. PubMed ID: 26049946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study.
    Ware NC; Pisarski EE; Haberer JE; Wyatt MA; Tumwesigye E; Baeten JM; Celum CL; Bangsberg DR
    AIDS Behav; 2015 May; 19(5):811-20. PubMed ID: 25267114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada.
    Leonardi M; Lee E; Tan DH
    Int J STD AIDS; 2011 Dec; 22(12):738-41. PubMed ID: 22174057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbicide research in developing countries: have we given the ethical concerns due consideration?
    Moodley K
    BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings.
    Paxton LA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):557-62. PubMed ID: 23032738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries.
    Scarlatti G
    AIDS Rev; 2004; 6(2):67-78. PubMed ID: 15332429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
    Eyakuze C; Jones DA; Starrs AM; Sorkin N
    Dev World Bioeth; 2008 Apr; 8(1):33-42. PubMed ID: 18315723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention.
    Bailey TC; Sugarman J
    Curr HIV Res; 2013 Sep; 11(6):473-80. PubMed ID: 24033297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Policy and practice, lost in transition: Reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda.
    Lubega M; Nsabagasani X; Tumwesigye NM; Wabwire-Mangen F; Ekström AM; Pariyo G; Peterson S
    Health Policy; 2010 May; 95(2-3):153-8. PubMed ID: 20022131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using HIV viral load to guide treatment-for-prevention interventions.
    Novitsky V; Essex M
    Curr Opin HIV AIDS; 2012 Mar; 7(2):117-24. PubMed ID: 22258501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical public health issues for the use of informal PrEP.
    Brisson J
    Glob Public Health; 2018 Oct; 13(10):1382-1387. PubMed ID: 28868979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.